Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-12-19 Purchase |
2024-12-20 07:35 am |
Prelude Therapeutics Inc | PRLD | Lim Bryant David CLO, Interim CFO, Corp Sec. |
25,000 | $0.9055 | $22,638 | 27,400 (Direct) |
View |
| 2023-05-24 Purchase |
2023-05-25 4:07 pm |
Prelude Therapeutics Inc | PRLD | Lim Bryant David Chief Legal Officer, Corp Sec. |
2,400 | $5.39 | $12,936 | 2,400 (Direct) |
View |
| 2021-03-25 Sale |
2021-03-29 4:09 pm |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP AND GENERAL COUNSEL |
7,630 | $1.3601 | $10,378 | 30,434 (Direct) |
View |
| 2021-01-12 Sale |
2021-01-12 7:08 pm |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP and General Counsel |
1,711 | $4.2091 | $7,202 | 89,064 (Direct) |
View |
| 2021-01-05 Sale |
2021-01-11 8:15 pm |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP and General Counsel |
1,465 | $3.9058 | $5,722 | 39,775 (Direct) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2025-02-04 Option Award |
2025-02-05 4:34 pm |
N/A 2035-02-04 |
Prelude Therapeutics Inc | PRLD | Lim Bryant David CLO, CFO, Corp Sec. |
200,000 | $0 | 200,000 (Direct) |
View |
| 2024-05-14 Option Award |
2024-05-16 4:00 pm |
N/A 2034-05-13 |
Prelude Therapeutics Inc | PRLD | Lim Bryant David CLO, Interim CFO, Corp Sec. |
25,000 | $0 | 25,000 (Direct) |
View |
| 2024-03-01 Option Award |
2024-03-04 6:07 pm |
N/A 2034-02-28 |
Prelude Therapeutics Inc | PRLD | Lim Bryant David Chief Legal Officer, Corp Sec. |
150,000 | $0 | 150,000 (Direct) |
View |
| 2023-03-01 Option Award |
2023-03-02 4:06 pm |
N/A 2033-02-28 |
Prelude Therapeutics Inc | PRLD | Lim Bryant David Chief Legal Officer, Corp Sec. |
250,000 | $0 | 250,000 (Direct) |
View |
| 2023-01-20 Option Award |
2023-02-02 8:08 pm |
N/A 2033-01-20 |
Aceragen Inc. | ACGN | Lim Bryant David SVP AND GENERAL COUNSEL |
25,400 | $0 | 25,400 (Direct) |
View |
| 2023-01-06 Option Award |
2023-01-10 9:17 pm |
N/A N/A |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP AND GENERAL COUNSEL |
399,218 | $0 | 309,695 (Direct) |
View |
| 2023-01-06 Tax Withholding |
2023-01-10 9:17 pm |
N/A N/A |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP AND GENERAL COUNSEL |
119,957 | $0.7099 | 309,695 (Direct) |
View |
| 2022-07-06 Option Award |
2022-07-07 5:33 pm |
N/A 2032-07-06 |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP AND GENERAL COUNSEL |
66,500 | $0 | 66,500 (Direct) |
View |
| 2022-04-01 Option Award |
2022-04-04 5:44 pm |
N/A 2032-04-01 |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP AND GENERAL COUNSEL |
41,500 | $0 | 41,500 (Direct) |
View |
| 2022-01-24 Option Award |
2022-01-26 8:43 pm |
N/A 2032-01-24 |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP AND GENERAL COUNSEL |
25,000 | $0 | 25,000 (Direct) |
View |
| 2021-07-08 Option Award |
2021-07-12 4:05 pm |
N/A 2031-07-08 |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP AND GENERAL COUNSEL |
66,500 | $0 | 66,500 (Direct) |
View |
| 2021-01-08 Option Award |
2021-01-12 7:08 pm |
N/A 2031-01-08 |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP and General Counsel |
51,000 | $0 | 89,064 (Direct) |
View |
| 2020-07-21 Option Award |
2020-07-23 4:37 pm |
N/A 2030-07-21 |
IDERA PHARMACEUTICALS INC. | IDRA | Lim Bryant David SVP and General Counsel |
50,000 | $0 | 50,000 (Direct) |
View |